These tumors can be treated with tyrosine kinase inhibitors (TKIs) [22], such as lenvatinib and sorafenib for DTC, dabrafenib, trametinib, and vemurafenib for BRAF mutated PTC or ATC, cabozantinib and vandetanib for MTC, or selpercaptinib in RET mutated MTCs [10,23,24]. Here, BRAF is linked to medullary thyroid gland carcinoma.